CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy

Dement Geriatr Cogn Disord. 2010;29(6):530-3. doi: 10.1159/000314679. Epub 2010 Jul 1.

Abstract

Objective: Our purpose was to measure Abeta(1-42), T-tau and P-tau(181) in the cerebrospinal fluid (CSF) of patients with posterior cortical atrophy (PCA), a presenile dementia likely to represent a variant of Alzheimer's disease (AD).

Methods: CSF samples from 34 subjects including 9 patients with PCA, 11 age-matched patients with AD and 14 age-matched cognitively healthy controls were analyzed using commercially available ELISA kits.

Results: The Abeta(1-42), T-tau and P-tau(181) levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD.

Conclusion: High T-tau and P-tau(181) and low Abeta(1-42) levels in PCA - typically observed in AD - indicate that the underlying pathology of PCA is usually AD. If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Alzheimer Disease / cerebrospinal fluid*
  • Alzheimer Disease / classification
  • Alzheimer Disease / pathology
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Atrophy / cerebrospinal fluid
  • Biomarkers / cerebrospinal fluid
  • Brain / pathology*
  • Case-Control Studies
  • Cognition Disorders / cerebrospinal fluid*
  • Cognition Disorders / pathology
  • Dementia / cerebrospinal fluid*
  • Dementia / classification
  • Dementia / pathology
  • Female
  • Humans
  • Male
  • Matched-Pair Analysis
  • Middle Aged
  • Peptide Fragments / cerebrospinal fluid*
  • Reference Values
  • tau Proteins / cerebrospinal fluid*

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • tau Proteins